It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical information request
Medical information request

PANGAEA

PANGAEA is a prospective, multi-center, non-interventional study of fingolimod, conducted in Germany, to investigate long-term safety and tolerability of fingolimod in daily clinical practice in patients with RRMS (N=4019)

Incidence of AEs and SAEs1

Pangaea table 1-v

Study discontinuation due to AEs1

Pangaea table 2-v
Download pdf
border


Incidence of AEs and SAEs: Switch from other DMTs2

Pangaea table 3-v
Natalizumab group – Most recent DMT at baseline was natalizumab
Non-natalizumab group – Most recent DMT at baseline was not natalizumab
*One case of PML
Link to article DoI
border
Abbreviations
AE, adverse event; DMT, disease modifying therapy; RRMS, relapsing-remitting multiple sclerosis; PANGAEA, Post-Authorization Non-interventional German sAfety of GilEnyA; PML, progressive multifocal leukoencephalopathy; SAE, serious AE
References
1. Ziemssen T, et al. Poster presented at the Annual Meeting 2019, Association of British Neurologists (ABN), 21–23 May 2019, The EICC, Edinburgh, Scotland. P167
2. Ziemssen T, et al. Mult Scler Relat Dis. 2020;39:101893.
* Indication wording varies in different countries. The current website is a global information resource. Local Prescribing Information/ Summary of Product Characteristics approved by individual country’s regulatory authority is the primary source of information for the indication of fingolimod in the individual country.